AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug
Synopsis
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma.
AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.
The company invested $445 million to expand the facility, it said. The unveiling follows the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia.
The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.
The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.